Reference number(s)
4330-A

SPECIALTY GUIDELINE MANAGEMENT

VEKLURY (remdesivir)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication[1]
Treatment of adults and pediatric patients (12 years of age and older and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: medical records documenting positive COVID-19 infection, estimated glomerular filtration rate (eGFR), hepatic laboratory testing, and prothrombin time.

III. CRITERIA FOR INITIAL APPROVAL

Treatment of COVID-19
Authorization of 30 days may be granted for treatment of COVID-19 when all of the following criteria are met:
A. Member has a confirmed active infection with COVID-19
B. Member is 12 years of age or older and weighs at least 40 kg
C. Member has eGFR ≥ 30 mL/min
D. Member is sufficiently ill to require hospitalization
E. Renal function, hepatic function, and prothrombin time have been taken prior to starting Veklury and will be monitored while receiving therapy as clinically appropriate
F. Member will receive a loading dose of 200mg on Day 1 followed by maintenance dose of 100mg per day starting Day 2
G. Member will not receive a total duration of therapy of greater than 10 days for an individual infection
H. Veklury will not be administered in combination with chloroquine or hydroxychloroquine
I. Veklury will be administered in a hospital or healthcare setting capable of providing acute care comparable to inpatient hospital care

IV. REFERENCES

1. Veklury [package insert]. Foster City, CA: Gilead Sciences, Inc.; October 2020.